Oramed Pharmaceuticals Inc. $ORMP

What the company doesAI summary of filing

Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral drug delivery technologies. The company's primary focus has been on ORMD-0801, an oral insulin capsule candidate for type 2 diabetes, though a Phase 3 trial (ORA-D-013-1) announced in January 2023 did not meet its primary or secondary endpoints, leading the company to discontinue oral insulin clinical activities for type 2 diabetes and pursue a new Phase 3 protocol for a subpopulation of patients. The company is also evaluating other pipeline candidates including an oral COVID-19 vaccine and exploring strategic opportunities. Oramed is pre-revenue from product sales, dependent on partnerships for development, manufacturing, and commercialization, and holds minority investments in several other companies including Nano, DNA, Entera, Alpha Tau, Pelthos, Lifeward, and Scilex. [10-K 2026-03-26]

Segments: Oral insulin capsule (ORMD-0801), Oral COVID-19 vaccine, Investments in other companies (Nano, DNA, Entera, Alpha Tau, Pelthos, Lifeward, Scilex), Real estate investments